NOVEL OMEGA 3 CARRIER PREPARATIONS FOR INHALATION DRUG DELIVERY FOR TREATING LUNG INFLAMMATION
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Sep 19, 2024
app pub date -
Aug 3, 2022
filing date -
Aug 4, 2021
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Inflammatory disorders of the lung are induced by COVID-19 disease, asthma, and numerous other disorders. Omega-3 fatty acids (O3FA), particularly docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) or cicosapentaenoic acid (EPA), have known anti-inflammatory and pro-resolving properties. Reduction of lung pathology and inflammation will be accomplished by a mixture incorporating O3FA that is suitable for nebulization using formulas and nebulization apparatus known in the art. The O3FA may be delivered in the form of ethyl esters (EE) or free fatty acid (FEA) oils or non-phosphate-containing glycerolipids or as phospholipids (PL) or as any other form known in the art. The mixture can also be delivered in any of the other forms of inhaled droplet or solids for inhalation known in the art. The patient will inhale for a therapeutically effective period of time to reduce inflammation and improve breathing.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully